Donald Trump announces a phased tariff plan targeting imported generic medicines, aiming to reshore drug manufacturing to the United States. Under the proposal, the tariff on imported generics is set at 0% for the first two years, followed by increases to 100% and then 200% over subsequent phases. Multiple outlets report that the plan is scheduled to begin in August 2026 and unfold over about three years.
Indian companies supplying generic drugs are described as highly exposed because India is a major global source of affordable generics, often referred to as the “pharmacy of the world.” NDTV notes that Indian generic medicines account for nearly 40% of the U.S. market by volume, underscoring the potential scale of any price or supply changes in response to higher import costs.
Mint reports that India’s pharma sector is taking a “wait-and-watch” approach as companies assess likely effects on pricing, demand, and supply chains. Times of India adds that the policy introduces uncertainty into existing bilateral trade arrangements between India and the U.S., as firms try to understand how the tariff schedule could affect trade and manufacturing decisions.
